Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Transplant Rejection Clear all
Completed Not applicable Interventional

IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection

NCT00351559
View directory record Official record
Conditions
Graft Rejection, Heart Diseases
Interventions
AlloMap molecular expression testing, Right ventricular endomyocardial biopsy
Device · Procedure
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational

MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients

NCT03822442
View directory record Official record
Conditions
Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients

NCT00466804
View directory record Official record
Conditions
Heart Transplant
Interventions
Heart transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
12
States / cities
San Francisco, California • Chicago, Illinois • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

NCT01757730
View directory record Official record
Conditions
Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
Interventions
Not listed
Lead sponsor
Arunark Kolipaka
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

Trifecta-Heart cfDNA-MMDx Study

NCT04707872
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
MMDx diagnostic test, Prospera, HLA antibody
Diagnostic Test
Lead sponsor
University of Alberta
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Little Rock, Arkansas • Tampa, Florida • West New York, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 11:00 AM EDT
Terminated Phase 1 Interventional

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

NCT01848301
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Interventions
Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
Device · Drug · Procedure
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

NCT00761787
View directory record Official record
Conditions
Graft Rejection, Heart Disease
Interventions
Not listed
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

NCT06939751
View directory record Official record
Conditions
Cardiac Failure, Graft Rejection
Interventions
Not listed
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 99 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation

NCT00962377
View directory record Official record
Conditions
Graft Rejection, Heart Diseases
Interventions
Endomyocardial biopsy, AlloMap Molecular Testing
Procedure
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Withdrawn No phase listed Observational

Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study

NCT00572286
View directory record Official record
Conditions
Advanced Heart Failure, Heart Transplantation
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2009 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

NCT02178943
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational

The TOGETHER Project - Heart

NCT03833050
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

NCT04610320
View directory record Official record
Conditions
Allosensitization, Heart Transplant Failure and Rejection
Interventions
Daratumumab-SC
Drug
Lead sponsor
Ronald Witteles
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting No phase listed Observational

Surveillance HeartCare® Outcomes Registry

NCT03695601
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Standard of Care
Other
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting Not applicable Interventional

Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant

NCT04380311
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
Tacrolimus Dosing Support Tool
Device
Lead sponsor
University of Utah
Other
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 3 Interventional

Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients

NCT00169936
View directory record Official record
Conditions
Heart Transplantation
Interventions
Magnetocardiograph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting Phase 2Phase 3 Interventional

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

NCT07079735
View directory record Official record
Conditions
CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting Not applicable Interventional

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

NCT05732779
View directory record Official record
Conditions
Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Interventions
DOT intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Coral Gables, Florida • Gainesville, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational

Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection

NCT01985412
View directory record Official record
Conditions
Cardiac Transplant Rejection, Lung Transplant Rejection
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Santa Clara, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting No phase listed Observational

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

NCT05205551
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting Phase 3 Interventional

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 22, 2026, 11:00 AM EDT